The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

被引：0
|
作者：
Lars Holger Ehlers
Mark Lamotte
Sofia Monteiro
Susanne Sandgaard
Pia Holmgaard
Evan C. Frary
Niels Ejskjaer
机构：
[1] Aalborg University,Department of Clinical Medicine
[2] IQVIA Real World Solutions,Steno Diabetes Center North Denmark
[3] IQVIA Real World Solutions,Department of Endocrinology
[4] Boehringer Ingelheim Danmark A/S,undefined
[5] Aalborg University Hospital,undefined
[6] Aalborg University Hospital,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Cardiovascular outcomes; Cost-effectiveness; Diabetes type 2; Empagliflozin; Liraglutide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1523 / 1534
页数：11
相关论文
共 50 条
  • [41] The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
    Lars H. Ehlers
    Mark Lamotte
    Mafalda C. Ramos
    Susanne Sandgaard
    Pia Holmgaard
    Malene M. Kristensen
    Niels Ejskjaer
    [J]. Diabetes Therapy, 2022, 13 : 489 - 503
  • [42] INCRETIN THERAPY FOR PATIENTS WITH TYPE 2 DIABETES IN SPAIN: A COST-EFFECTIVENESS ANALYSIS OF LIRAGLUTIDE VERSUS SITAGLIPTIN
    Ramirez de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
  • [43] Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
    Ericsson, Asa
    Glah, Divina
    Lorenzi, Maria
    Jansen, Jeroen P.
    Fridhammar, Adam
    [J]. PLOS ONE, 2018, 13 (02):
  • [44] Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
    Mannucci, Edoardo
    Ghetti, Gianni
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2022, 23 (01) : 85 - 95
  • [45] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN THE TREATMENT OF T2D WITH PREVIOUS CARDIOVASCULAR DISEASE IN ITALY
    Iannazzo, S.
    Mannucci, E.
    Reifsnider, O.
    Maggioni, A. P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [46] Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
    Perez, Antonio
    Mezquita Raya, Pedro
    Ramirez de Arellano, Antonio
    Briones, Teresa
    Hunt, Barnaby
    Valentine, William J.
    [J]. DIABETES THERAPY, 2015, 6 (01) : 61 - 74
  • [47] Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
    Antonio Pérez
    Pedro Mezquita Raya
    Antonio Ramírez de Arellano
    Teresa Briones
    Barnaby Hunt
    William J. Valentine
    [J]. Diabetes Therapy, 2015, 6 : 61 - 74
  • [48] Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
    Mafalda Ramos
    Michael H. Cummings
    Anastasia Ustyugova
    Syed I. Raza
    Shamika U. de Silva
    Mark Lamotte
    [J]. Diabetes Therapy, 2020, 11 : 2041 - 2055
  • [49] Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 791 - 799
  • [50] Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
    Ramos, Mafalda
    Cummings, Michael H.
    Ustyugova, Anastasia
    Raza, Syed, I
    de Silva, Shamika U.
    Lamotte, Mark
    [J]. DIABETES THERAPY, 2020, 11 (09) : 2041 - 2055
12345